KDOQI 2019 Vascular Access Guidelines: What Is New

Abstract

The new Kidney Disease Outcomes Quality Initiative (KDOQI) Vascular Access Guidelines have a patient focus for comprehensive vascular access management. The patient's unique circumstances and individualized needs are the foundation of their dialysis access strategy, which is interlinked with the patient's End Stage Kidney Disease (ESKD) Life-Plan. The ESKD Life-Plan is an individualized and comprehensive map for dialysis modalities and vascular access for the lifetime of the patient. New targets are introduced that align with this patient-centered approach. They are less detail prescriptive than prior vascular access guidelines, giving opportunity for vascular access management at the clinician's discretion, partly in consideration of constraints of local resources and available expertise; however, the guidelines also emphasize the importance of high-quality standards with defined targets for achieving the guideline's overarching goal for vascular access care. The guidelines made significant changes relevant to the interventionalist, including selective use of vessel mapping in planning for vascular access, choice of vascular access that allows for considering endovascular access creations, and endovascular treatment (e.g., angioplasty, stent graft insertions) based on clinical indicators found on routine clinical monitoring. To that end, preemptive angioplasty of fistulas and grafts with stenosis, not associated with clinical indicators, is not recommended. New content in these guidelines also includes the use of stent grafts and management of central venous stenosis. The new KDOQI Vascular Access Guidelines 2019 represent a rigorous review of the evidence; however, the available evidence to guide vascular access practice remains limited. There is a significant need and opportunity for new and ongoing high-quality research to inform best practice.

Keywords

hemodialysis - vascular access - chronic kidney disease - end-stage kidney disease - guideline - interventional radiology

Disclosures/Funding

C.E.L. is Chair of the KDOQI Vascular Access Guideline working group.

D.K.R. is a member of the KDOQI Vascular Access Guideline working group.

There are no financial disclosures.

Publication History

Article published online:
18 February 2022

• References

• 1 Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int 2019; 96 (05) 1048-1050
• 2 Liyanage T, Ninomiya T, Jha V. et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 2015; 385 (9981): 1975-1982
• 3 Lok CE, Huber TS, Lee T. et al; National Kidney Foundation. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis 2020; 75 (4, Suppl 2): S1-S164
• 4 Pisoni RL, Zepel L, Fluck R. et al. International differences in the location and use of arteriovenous accesses created for hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2018; 71 (04) 469-478
• 5 Dawoud D, Lok CE, Waheed U. Recent advances in arteriovenous access creation for hemodialysis: new horizons in dialysis vascular access. Adv Chronic Kidney Dis 2020; 27 (03) 191-198
• 6 Trerotola SO, Lawson J, Roy-Chaudhury P, Saad TF. Lutonix AV Clinical Trial Investigators. Drug coated balloon angioplasty in failing AV fistulas: a randomized controlled trial. Clin J Am Soc Nephrol 2018; 13 (08) 1215-1224
• 7 Lookstein RA, Haruguchi H, Ouriel K. et al; IN.PACT AV Access Investigators. Drug-coated balloons for dysfunctional dialysis arteriovenous fistulas. N Engl J Med 2020; 383 (08) 733-742